Shares of GlaxoSmithKline are lower on Wednesday after the drugmaker cut its full-year earnings outlook.
Bill Ackman's presentation failed to impress investors, but it probably should have, as Ackman raised several important points.
Leafly is a website that helps cannabis consumers research over 800 cannabis strains and find reputable locations to purchase the right strain.
Investors are still focused on the the looming approval of generic Copaxone.
The stream of companies undergoing inversions will continue until the U.
Here are some technical guidelines that you may be able to profit from.
AbbVie's buyout of Shire reduces taxes but also grows its drug pipeline and adds cash flow.
Drugmaker AbbVie has clinched a deal worth about $55 billion to acquire British rival Shire in the biggest tax inversion deal by a U.S. company.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
U.S. stock futures are mixed as investors are spooked by the Malaysia Airlines jet crash in Ukraine; AbbVie succeeds in buying Shire; GE profit meets estimates.
Novartis (NVS) shares are down after the drug company reported second quarter earnings and revenue that missed analysts expectations.
It's not often an investor gets the opportunity to buy a biotech stock with two blockbuster indications in the pipeline and major catalysts only months away at such a discount.
Expect bargain hunters to start snapping up shares.
Dicerna is aiming to treat diseases that have never been treated before and that could lead to a quick FDA approval.
The Seattle Genetics' bull thesis will be tested when results are announced from the "AETHERA" study of Adcetris in post-stem cell transplant Hodgkin's lymphoma patients.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV